Teva Pharmaceuticals (NYSE:TEVA) just served up some serious growth numbers in its Q3 2024 report, turning heads with a $4.3 billion revenuea 13% boost from last year's numbers. With its U.S ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) said the FDA has expanded labeling for its biosimilar of Johnson & Johnson’s (JNJ) Stelara to include the treatment of Crohn ...

Wednesday, Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year, or ...

That's why Men’s Health's 2024 Fall Style Guide is highlighting apparel that can handle the great outdoors that look stylish enough to wear on a daily basis. We're talking rugged classics like ...

Teva Zaveroni hails the performances of rising star Heimanu Terorotua at the OFC Beach Soccer Nations Cup and backs Tahiti to shine at Seychelles 2025. Not many people know that Teva Zaveroni, the ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...

Shares of Teva Pharmaceutical Industries Ltd. (TEVA) have gained 2.9% over the past four weeks to close the last trading session at $18.25, but there could still be a solid upside left in the ...

BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its ...

Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales ...